Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress

Fig. 5

Treatment with rAAV.EpoR76E increases expression of several antioxidant proteins and increases H-ferritin in the retina. ac Representative confocal micrographs of H-ferritin immunolabeling in retinas from 3-month controls (a), 8-month-old mice injected with rAAV.eGFP (b), and 8-month-old mice treated with rAAV.EpoR76E (c). d Bar graph quantification of H-ferritin immunofluorescence showing a statistically significant increase in the rAAV.EpoR76E-treated group as compared to rAAV.eGFP-injected mice. e Bar graph of mRNAs with increased expression in 8-month glaucomatous retina as compared to 3-month controls regardless of treatment. f Bar graph of mRNAs with increased expression in retinas from rAAV.EpoR76E-treated 8-month-old mice as compared to age-matched rAAV.eGFP-injected mice

Back to article page